• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Replimune Group, Inc. - Common Stock (NQ:REPL)

    10.73 +0.54 (+5.35%)
    Streaming Delayed Price Updated: 10:46 AM EDT, Jun 22, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 623,098
    Open 10.22
    Bid (Size) 10.74 (400)
    Ask (Size) 10.75 (100)
    Prev. Close 10.19
    Today's Range 10.19 - 10.89
    52wk Range 1.500 - 13.24
    Shares Outstanding 46,772,263
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗
    Mornings like we had on Wednesday are exactly why I get up and do this show every single day the market is open. UniQure NV (QURE) opened around $43. Touched $48.88 intraday. Closed in the high $47s.... 
    Via InvestorPlace
    News headline image
    Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
    From Replimune, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +20.6%
    +20.6%
    1 Month
    +118.6%
    +118.6%
    3 Month
    +53.8%
    +53.8%
    6 Month
    +8.1%
    +8.1%
    1 Year
    +16.3%
    +16.3%

    More News

    Read More
    News headline image
    Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
    From Replimune, Inc.
    Via GlobeNewswire
    Top stock movements in today's session. ↗
    Via Chartmill
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    Top movers in Friday's pre-market session ↗
    Via Chartmill
    News headline image
    Replimune Announces Planned RP1 BLA Resubmission Following Productive Discussion with FDA
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REPL Investors Have Opportunity to Join Replimune Group, Inc. Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Replimune to Present at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Replimune Group, Inc. - REPL
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    The trading volume of these stocks is deviating from the norm in today's session. ↗
    Via Chartmill
    Topics Artificial Intelligence
    News headline image
    Which stocks are moving on Monday? ↗
    Via Chartmill
    News headline image
    What's going on in today's session ↗
    Via Chartmill
    News headline image
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Which stocks are moving before the opening bell on Monday? ↗
    Via Chartmill
    News headline image
    Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    Replimune to Present at Two Upcoming Investor Conferences
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Replimune, Inc.
    Via GlobeNewswire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    These stocks are moving in today's after hours session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Replimune Group, Inc. - Common Stock publicly traded?
    Yes, Replimune Group, Inc. - Common Stock is publicly traded.
    What exchange does Replimune Group, Inc. - Common Stock trade on?
    Replimune Group, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Replimune Group, Inc. - Common Stock?
    The ticker symbol for Replimune Group, Inc. - Common Stock is REPL on the Nasdaq Stock Market
    What is the current price of Replimune Group, Inc. - Common Stock?
    The current price of Replimune Group, Inc. - Common Stock is 10.73
    When was Replimune Group, Inc. - Common Stock last traded?
    The last trade of Replimune Group, Inc. - Common Stock was at 06/22/26 10:46 AM ET
    What is the market capitalization of Replimune Group, Inc. - Common Stock?
    The market capitalization of Replimune Group, Inc. - Common Stock is 502.10M
    How many shares of Replimune Group, Inc. - Common Stock are outstanding?
    Replimune Group, Inc. - Common Stock has 502M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.